These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 36328146)

  • 1. Proteomics reveals antiviral host response and NETosis during acute COVID-19 in high-risk patients.
    Bauer A; Pachl E; Hellmuth JC; Kneidinger N; Heydarian M; Frankenberger M; Stubbe HC; Ryffel B; Petrera A; Hauck SM; Behr J; Kaiser R; Scherer C; Deng L; Teupser D; Ahmidi N; Muenchhoff M; Schubert B; Hilgendorff A
    Biochim Biophys Acta Mol Basis Dis; 2023 Feb; 1869(2):166592. PubMed ID: 36328146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV.
    Stukalov A; Girault V; Grass V; Karayel O; Bergant V; Urban C; Haas DA; Huang Y; Oubraham L; Wang A; Hamad MS; Piras A; Hansen FM; Tanzer MC; Paron I; Zinzula L; Engleitner T; Reinecke M; Lavacca TM; Ehmann R; Wölfel R; Jores J; Kuster B; Protzer U; Rad R; Ziebuhr J; Thiel V; Scaturro P; Mann M; Pichlmair A
    Nature; 2021 Jun; 594(7862):246-252. PubMed ID: 33845483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma proteomics identify potential severity biomarkers from COVID-19 associated network.
    Sahin AT; Yurtseven A; Dadmand S; Ozcan G; Akarlar BA; Kucuk NEO; Senturk A; Ergonul O; Can F; Tuncbag N; Ozlu N
    Proteomics Clin Appl; 2023 Mar; 17(2):e2200070. PubMed ID: 36217943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted proteomics identifies circulating biomarkers associated with active COVID-19 and post-COVID-19.
    Zoodsma M; de Nooijer AH; Grondman I; Gupta MK; Bonifacius A; Koeken VACM; Kooistra E; Kilic G; Bulut O; Gödecke N; Janssen N; Kox M; Domínguez-Andrés J; van Gammeren AJ; Ermens AAM; van der Ven AJAM; Pickkers P; Blasczyk R; Behrens GMN; van de Veerdonk FL; Joosten LAB; Xu CJ; Eiz-Vesper B; Netea MG; Li Y
    Front Immunol; 2022; 13():1027122. PubMed ID: 36405747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization by Quantitative Serum Proteomics of Immune-Related Prognostic Biomarkers for COVID-19 Symptomatology.
    Villar M; Urra JM; Rodríguez-Del-Río FJ; Artigas-Jerónimo S; Jiménez-Collados N; Ferreras-Colino E; Contreras M; de Mera IGF; Estrada-Peña A; Gortázar C; de la Fuente J
    Front Immunol; 2021; 12():730710. PubMed ID: 34566994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetic Multi-omic Analysis of Responses to SARS-CoV-2 Infection in a Model of Severe COVID-19.
    Cantwell AM; Singh H; Platt M; Yu Y; Lin YH; Ikeno Y; Hubbard G; Xiang Y; Gonzalez-Juarbe N; Dube PH
    J Virol; 2021 Sep; 95(20):e0101021. PubMed ID: 34319784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virus-Host Interactome and Proteomic Survey Reveal Potential Virulence Factors Influencing SARS-CoV-2 Pathogenesis.
    Li J; Guo M; Tian X; Wang X; Yang X; Wu P; Liu C; Xiao Z; Qu Y; Yin Y; Wang C; Zhang Y; Zhu Z; Liu Z; Peng C; Zhu T; Liang Q
    Med; 2021 Jan; 2(1):99-112.e7. PubMed ID: 32838362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal proteomic profiling provides insights into host response and proteome dynamics in COVID-19 progression.
    Lee JS; Han D; Kim SY; Hong KH; Jang MJ; Kim MJ; Kim YG; Park JH; Cho SI; Park WB; Lee KB; Shin HS; Oh HS; Kim TS; Park SS; Seong MW
    Proteomics; 2021 Jun; 21(11-12):e2000278. PubMed ID: 33945677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteo-Genomic Analysis of SARS-CoV-2: A Clinical Landscape of Single-Nucleotide Polymorphisms, COVID-19 Proteome, and Host Responses.
    Tushir S; Kamanna S; Nath SS; Bhat A; Rose S; Aithal AR; Tatu U
    J Proteome Res; 2021 Mar; 20(3):1591-1601. PubMed ID: 33555895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets.
    Bojkova D; Klann K; Koch B; Widera M; Krause D; Ciesek S; Cinatl J; Münch C
    Nature; 2020 Jul; 583(7816):469-472. PubMed ID: 32408336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individual COVID-19 disease trajectories revealed by plasma proteomics.
    Memon D; Barrio-Hernandez I; Beltrao P
    EMBO Mol Med; 2021 Aug; 13(8):e14532. PubMed ID: 34260159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a special cell type as a determinant of the kidney tropism of SARS-CoV-2.
    Lin H; Ma X; Xiao F; Su H; Shi Y; Liu Y; Song L; Zhang Z; Zhang C; Peng H
    FEBS J; 2021 Sep; 288(17):5163-5178. PubMed ID: 34228902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ubiquitin-Modified Proteome of SARS-CoV-2-Infected Host Cells Reveals Insights into Virus-Host Interaction and Pathogenesis.
    Zhang H; Zheng H; Zhu J; Dong Q; Wang J; Fan H; Chen Y; Zhang X; Han X; Li Q; Lu J; Tong Y; Chen Z
    J Proteome Res; 2021 May; 20(5):2224-2239. PubMed ID: 33666082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mass spectrometry-based proteomic platforms for better understanding of SARS-CoV-2 induced pathogenesis and potential diagnostic approaches.
    Ahsan N; Rao RSP; Wilson RS; Punyamurtula U; Salvato F; Petersen M; Ahmed MK; Abid MR; Verburgt JC; Kihara D; Yang Z; Fornelli L; Foster SB; Ramratnam B
    Proteomics; 2021 May; 21(10):e2000279. PubMed ID: 33860983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
    Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
    Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomics in the COVID-19 Battlefield: First Semester Check-Up.
    Grenga L; Armengaud J
    Proteomics; 2021 Jan; 21(1):e2000198. PubMed ID: 33236484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial.
    Aricò E; Castiello L; Bracci L; Urbani F; Lombardo F; Bacigalupo I; Ancidoni A; Vanacore N; Falcione A; Reggiani C; Dutti GM; Maglie MG; Papa O; Bartoletti PL; Ozzella G; Bevilacqua N; Nicastri E; Belardelli F; Sconocchia G
    Trials; 2021 Sep; 22(1):584. PubMed ID: 34479601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.